ClinicalTrials.gg
RecruitingNCT06165302Updated Oct 29, 2026

Exercise in Prostate Cancer

An interventional study of Exercise Intervention in Prostate Cancer Metastatic and Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 29, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — 12 open to participants now, 18 under way, none of them phase 3. Prostatic Neoplasms · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Planned enrollment
41st of 72
20 · median 25
Started
2025
with 5 others
No phase
15 of 78
4 open now
Primary completion
2029-03
later than 12 of 17 live
Registered
70th of 78
by date

Among the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, this one is the 41st largest by planned enrollment of the 72 interventional ones that give a count, is one of 6 that started in 2025, is one of 15 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 70th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline screening assessments, followed by 12 weeks of exercise intervention, and then follow-up assessments 12 weeks after the end of the exercise intervention.

Read the detailed description

This is a pilot single arm prospective study of personalized exercise training in men with metastatic castration resistant prostate cancer who are being treated with or without oral anti-androgens. The primary objective is to determine if combination of resistance and aerobic exercises lowers CTCs in men with mCRPC. Researchers will assess the rate of conversion from CTC positive to CTC negative in participants at the end of the 12 week exercise intervention. The study will enroll 20 participants onto the trial with the goal of at least 10 participants having blood drawn at both baseline and 12 weeks and completed at least 75% of the prescribed exercise sessions. Participants will undergo follow-up assessments at the end of the 12 week exercise intervention and the study team will monitor participant records for 365 days after the study completion for vital status.

03

Conditions studied

  • Prostate Cancer Metastatic
  • Prostate Cancer

Browse trials for

Keywords

  • Exercise Intervention
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men with prostate adenocarcinoma
  2. Currently taking androgen deprivation therapy alone or with an oral androgen axis inhibitor (abiraterone, enzalutamide, darolutamide, or apalutamide are permitted) and have been on treatment for at least 3 months
  3. Elevated (PSA >= 1ng/mL) or rising PSA (any numerical increase based on at least 2 PSA readings at least 2 weeks apart)
  4. Any number of prior therapies (prior chemo, radium-223, etc.) is allowed
  5. CTC + at screening
  6. If a bone protective agent is to be started, it should be started at least 2 weeks prior to the onset of exercise intervention.
  7. (ECOG) performance status \<=1
  8. Clearance by cardiologist if under the current care of a cardiologist (seen in the past 1 year)
  9. Determined to be physically ready for exercise by PM\&R physician

Exclusion criteria

Exclusion Criteria:

  1. Small cell carcinoma of the prostate
  2. Unable to participate or monitor exercise compliance due to conditions such as impaired cognition
  3. Moderate to severe bone pain, including pain requiring the use of narcotics for prostate cancer related pain, or pain that limits any activities of daily living
  4. Clinical progression requiring a change in systemic therapy or the addition of palliative radiation for symptom control
  5. Bone in spine or long bones which, in the eye of the treating physician require referral to radiation oncology or surgery for management due to risk of fracture
  6. Significant cardiovascular disease or concurrent illness that would make exercise intervention for 12 weeks unsafe. If there is significant cardiovascular disease and the participant is under the care of a cardiologist (seen within the past 1 year), approval of the cardiologist to participate is required.
  7. Major surgery within the past 4 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Exercise Intervention

    Participants will be prescribed an exercise program after completing assessments at baseline. Participants will adhere to the prescribed exercise intervention for 12 weeks and log activity in a physical activity diary. Participants will return to clinic on Week 5 and Week 9 for assessments and adjustment to their exercise prescription as needed.

    Behavioral: Exercise Intervention

Interventions

  • BehavioralExercise Intervention

    12 weeks of prescribed exercise intervention.

06

What researchers measure

Primary outcomes

  1. Number of participants with negative CTC count

    Number of participants with negative CTC count at 12 weeks compared to the baseline

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Number of participants with change in cell free DNA levels

    Number of participants with change in cell free DNA levels from baseline to 12 weeks

    Time frame: Baseline, 12 weeks

  2. Number of participants with change in Cell free RNA levels

    Number of participants with change in cell free RNA levels from baseline to 12 weeks

    Time frame: Baseline, 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2029, 40 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 40 months is close to that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Oct 16, 2025
Primary completionEst.
Mar 1, 2029
CompletionEst.
Jan 30, 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Maximum age 80 Years→none; Sex ALL→MALE; 1 inclusion criterion edited, 2 added, 2 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedElevated (PSA >= 1ng/mL) or rising PSA (any numerical increase based on at least 2 PSA readings at least 2 weeks apart)
  • RemovedCTC + according to standard clinical grade laboratory test by androgen receptor isoform splice variant 7 (AR-V7) testing at Hopkins.
  • AddedCTC + at screening
  • RemovedAge <=80 years
  • AddedDetermined to be physically ready for exercise by PM\&R physician
Exclusion criteria
  • ChangedBefore Moderate to severe bone pain that limits any activities of daily living, including use of narcotics for prostate cancer related painNow Moderate to severe bone pain, including pain requiring the use of narcotics for prostate cancer related pain, or pain that limits any activities of daily living
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Johns Hopkins University · Baltimore, United StatesContact n•••@jh.edu · •••1017→T•••@jhmi.edu · •••6337
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility Maximum age 80 Years→none; Sex ALL→MALE; 1 inclusion criterion edited, 2 added, 2 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedElevated (PSA >= 1ng/mL) or rising PSA (any numerical increase based on at least 2 PSA readings at least 2 weeks apart)
    • RemovedCTC + according to standard clinical grade laboratory test by androgen receptor isoform splice variant 7 (AR-V7) testing at Hopkins.
    • AddedCTC + at screening
    • RemovedAge <=80 years
    • AddedDetermined to be physically ready for exercise by PM\&R physician
    Exclusion criteria
    • ChangedBefore Moderate to severe bone pain that limits any activities of daily living, including use of narcotics for prostate cancer related painNow Moderate to severe bone pain, including pain requiring the use of narcotics for prostate cancer related pain, or pain that limits any activities of daily living
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Johns Hopkins University · Baltimore, United StatesContact n•••@jh.edu · •••1017→T•••@jhmi.edu · •••6337
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06165302
Collaborators
Physical Medicine & Rehabilitation Educ Research Foundation, Inc
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Oct 16, 2025
Primary completion
Mar 1, 2029 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Oct 29, 2026

Study contacts

Rana Sullivan, RN
Contact
ProstateCancerClinicalTrials@live.johnshopkins.edu
410-614-6337
Cathy Marshall, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion